Log In Sign up
The largest database of trusted experimental protocols

Anti mouse pd l1 antibody

Manufactured by BioXCell
Visit Supplier
Sourced in United States

The Anti-mouse PD-L1 antibody is a laboratory reagent used in research applications. It binds to the PD-L1 protein found on mouse cells, enabling the study of the programmed cell death pathway. The antibody can be used in various immunological techniques, such as flow cytometry and immunohistochemistry, to investigate the role of PD-L1 in immune system function.

Automatically generated - may contain errors

Lab products found in correlation

Fetal bovine serum (fbs), by Thermo Fisher Scientific (3 mentions) Anti mouse pd 1 antibody, by BioXCell (2 mentions) Sulindac, by Merck Group (1 mentions) Colo205, by American Type Culture Collection (1 mentions) Nf κb inhibitor bay 11 7082, by Merck Group (1 mentions) Cell culture medium, by Thermo Fisher Scientific (1 mentions) Rat igg2b isotype control, by BioXCell (1 mentions) Ht 29, by American Type Culture Collection (1 mentions) Caco 2, by American Type Culture Collection (1 mentions) Rat igg, by BioXCell (1 mentions) Axitinib, by Pfizer (1 mentions) Axitinib, by BioXCell (1 mentions) Cell counting kit 8 (cck8), by Dojindo Laboratories (1 mentions) Be0101, by BioXCell (1 mentions) Ivis spectrum imaging system, by PerkinElmer (1 mentions) Anti mouse cd31, by BD (1 mentions) 3 3 diaminobenzidine kit, by Vector Laboratories (1 mentions) Goat anti rat secondary antibody, by Jackson ImmunoResearch (1 mentions) Horseradish peroxidase conjugated goat anti rabbit, by Jackson ImmunoResearch (1 mentions) Anti mouse cleaved caspase 3 antibody, by Cell Signaling Technology (1 mentions)

14 protocols using anti mouse pd l1 antibody

1

Evaluating TKI and ICI Effects on RenCa Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
In vitro growth inhibitory effects of TKI and/or ICI on RenCa cells were assessed using Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan). Briefly, 5 × 103 cells were seeded in each well of 96-well plates and allowed to attach overnight. The wells were treated with vehicle, axitinib (Pfizer, Inc., New York, NY, USA), anti-mouse PD-1 antibody (Bio X Cell, Lebanon, NH, USA), anti-mouse PD-L1 antibody (Bio X Cell), axitinib plus anti-mouse PD-1 antibody, or axitinib plus anti-mouse PD-L1 antibody. After 72 h of incubation, the number of cells was counted. Each assay was performed in triplicate.
Watanabe H., Matsushita Y., Tamura K., Motoyama D., Sugiyama T., Otsuka A, & Miyake H. (2023). Assessments of therapeutic effects according to timings for combined therapy with axitinib and immune check point inhibitor in a mouse renal cell carcinoma model. Scientific Reports, 13, 11361.
+ Open protocol
+ Expand
2

Tumor Slice Functional Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols
For the functional assays, the cultured organotypic tumor slices were treated with immunomodulators or cytotoxic agents for fixed time points. Tissue slices were treated with 1000 and 10,000U of mouse IFN-γ (Shenandoah Biotechnology, 200-16AF) for 48–60 hr; 10 μg of human anti PD-L1 antibody (Bioxcell, BE0285), mouse anti-PD-L1 antibody (Bioxcell, BE0101), anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) antibody (Bioxcell, BE0164), rat IgG2b,K (Bioxcell, BE0090) or mouse IgG2b (Bioxcell, BE0086) for 48 hr. Unstimulated and IgG treated slices served as controls and a minimum of 3 tumor slices were analyzed for each condition at the end of the assay (48–60 hr). Responses were measured by flow cytometry-based immunophenotyping or reverse-phase protein array. In addition to the lymphoid and myeloid panel used for immunophenotyping, functional assays included antibodies against activation and inhibitory markers: CD27, CD80, CD86, MHC-II, PD-1, PDL-1 and CD44 (Supplementary Table S1).
Sivakumar R., Chan M., Shin J.S., Nishida-Aoki N., Kenerson H.L., Elemento O., Beltran H., Yeung R, & Gujral T.S. (2019). Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery. Oncoimmunology, 8(12), e1670019.
+ Open protocol
+ Expand
3

Colorectal Cancer Cell Line Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols
The murine colon cancer cell line CT26 and the human colon cancer cell lines, Colo205, HT29, and Caco-2, were purchased from ATCC (Manassas VA, USA). We authenticate our cell lines at regular intervals of 12 months in addition to two authentications at the beginning and end of the project using the services provided by IDEXX BioAnalytics (Columbia, MO). The authentication includes short tandem repeat (STR) profiling, mycoplasma testing, and cross-species contamination checking. In this project, only early passages of the cell lines (<10) were utilized. Cell culture mediums were purchased from Thermo Fisher Scientific (Carlsbad CA, USA) and used for cell culture after mixing with 10% fetal bovine serum (Thermo Fisher Scientific). Cells were cultured at 37°C and in a 5% CO2 humidified incubator. Sulindac, CMC (Carboxymethylcellulose), and NF-κB inhibitor (Bay11-7082) were purchased from Sigma-Aldrich (St Louis MO, USA). CMC was used as the vehicle of Sulindac for in vivo study. Mouse anti-PD-L1 antibody and isotype control rat IgG2b were purchased from BioXcell (West Lebanon NH, USA). Sulindac sulfide was purchased from Alfa Aesar (Haverhill MA, USA).
Yi B., Cheng H., Wyczechowska D., Yu Q., Li L., Ochoa A.C., Riker A.I, & Xi Y. (2021). Sulindac modulates the response of proficient MMR colorectal cancer to anti-PD-L1 immunotherapy. Molecular cancer therapeutics, 20(7), 1295-1304.
+ Open protocol
+ Expand
4

Bispecific Antibody Generation Protocols

Check if the same lab product or an alternative is used in the 5 most similar protocols
A bispecific antibody to HER2 and hCD3 was generated by Fab arm exchange using anti-HER2 antibody (trastuzumab) and anti-human CD3 antibody (UCHT1). Bispecific antibody against hGPC3 and hCD3 was manufactured as full length human IgG4 by applying technologies for light chain commonization, heavy chain heterodimerization, and isoelectric point modification [Ishiguro, T. et al. Manuscript submitted]. Bispecific antibody against hGPC3 and mCD3 was generated by Fab arm exchange using anti-GPC3 antibody (GC33) and anti-mouse CD3 antibody (2C11). Anti-mouse PD-L1 antibody was purchased from BioXcell (clone: 10F.9G2).
Ueda O., Wada N.A., Kinoshita Y., Hino H., Kakefuda M., Ito T., Fujii E., Noguchi M., Sato K., Morita M., Tateishi H., Matsumoto K., Goto C., Kawase Y., Kato A., Hattori K., Nezu J., Ishiguro T, & Jishage K.I. (2017). Entire CD3ε, δ, and γ humanized mouse to evaluate human CD3–mediated therapeutics. Scientific Reports, 7, 45839.
+ Open protocol
+ Expand
5

Intratumoral Immunotherapy for Glioblastoma

Check if the same lab product or an alternative is used in the 5 most similar protocols
For tumor implantation, GL261 cells and its derivatives (5 × 104 cells/mouse) cells were grafted into the caudate nucleus of the 7 to 10-week old mice using a guide-screw system as previously described (5 (link)). The mice with implanted tumors were randomly assigned to experimental groups. Then the viruses (5 × 107 plaque-forming units (PFU)/mouse), the OX40 agonist antibody OX86 (25 μg/mouse; provided by the Monoclonal Antibody Core Facility at MD Anderson Cancer Center), the anti-mouse PD-L1 antibody and/or rat IgG (25 μg/mouse; Bio X Cell) were injected intratumorally. For rechallenging the surviving mice, GL261-5 (5 × 104 cells/mouse) or B16-F10 (1× 103 cells/mouse) cells were implanted in the same hemisphere previously implanted with the cured tumor or in the contralateral hemisphere of the mouse brain. All animal studies (except one survival study in athymic mice) were conducted in C57BL/6 mice. All experimental procedures involving the use of mice were done in accordance with protocols approved by the Animal Care and Use Committee of MD Anderson Cancer Center and followed National Institutes of Health and United States Department of Agriculture guidelines.
Jiang H., Rivera-Molina Y., Gomez-Manzano C., Clise-Dwyer K., Bover L., Vence L.M., Yuan Y., Lang F.F., Toniatti C., Hossain M.B, & Fueyo J. (2017). Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer research, 77(14), 3894-3907.
+ Open protocol
+ Expand
6

Combination Immunotherapy for Prostate Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols
On day -14, four- to six-week-old male FVB mice were transplanted with 3 × 106 Myc-CaP cells by subcutaneous injection. On day 0, following the implantation of tumor cells, the mice were castrated by surgery. The mice were treated with 20 μg human IgG, mouse IFNα4 (produced in house), anti-mouse PD-L1 antibody (Bioxcell, clone 10F.9G2, Lebanon, NH, USA), anti-mouse CTLA-4 antibody (produced in house), anti-mouse 4-1BB antibody (Bioxcell, clone 3H3), mouse IL-2 (produced in house), or mouse IL-9 (produced in house) on days 14, 17, and 21, by intratumoral injection. For cell depletion experiments, 200 μg YTS.169.4.2 (anti-mouse CD8 antibody, produced in house), GK1.5 (anti-mouse CD4 antibody, produced in house), or PK136 (anti-mouse NK1.1 antibody, produced in house) on days 14 and 17, by intraperitoneal injection.
Fan L., Xu G., Cao J., Li M., Zhang H., Li F., Qi X., Zhang X., Li Z., Han P, & Yang X. (2021). Type I Interferon Promotes Antitumor T Cell Response in CRPC by Regulating MDSC. Cancers, 13(21), 5574.
+ Open protocol
+ Expand
7

Evaluating Anti-Tumor and Anti-Metastatic Effects of sHDL-Based Treatments

Check if the same lab product or an alternative is used in the 5 most similar protocols
4T1 tumor models were established as described above. The mice were randomly divided into six groups (n = 7) when tumor volumes reached ∼100 mm3 and were intravenously injected with PBS, sHDL, LEN, V-sHDL, L-sHDL, or LV-sHDL (LEN: 0.5 mg/kg, vadimezan: 2 mg/kg; 1:6 mol/mol, one injection every 4 days for three injections), respectively. Mice bearing luciferase-expressing 4T1 tumors were used to further assess the anti-metastasis activity of the treatments (n = 4). d-Luciferin potassium salt (MB1834-2, Meilun) was injected i.p. 14 days after treatment and images were captured through an IVIS Spectrum imaging system (PerkinElmer, Waltham, MA, USA). Anti-mouse PD-L1 antibody (BE0101, BioXcell, West Lebanon, NH, USA) was injected intraperitoneally at 50 μg per mouse twice (one injection every 7 days). The long (L) and short (W) axis of the tumors, body weight, and survival were monitored every other day. The volume of the tumors was calculated by Eq. (3): Volume=(L×W2)/2
Zheng C., Zhang W., Wang J., Zhai Y., Xiong F., Cai Y., Gong X., Zhu B., Zhu H.H., Wang H., Li Y, & Zhang P. (2022). Lenvatinib- and vadimezan-loaded synthetic high-density lipoprotein for combinational immunochemotherapy of metastatic triple-negative breast cancer. Acta Pharmaceutica Sinica. B, 12(9), 3726-3738.
+ Open protocol
+ Expand
8

Tissue-Specific Immunohistochemistry Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Haematoxylin and eosin staining was performed on the cryosections (10 μm) of different tissues, including heart, lung, liver, spleen, intestine and skin from healthy or MPE mice. For immunofluorescence staining of T cells, cryosections (10 μm) of LLC-Luc lung MPE-bearing tumour tissues obtained from the above treatment group were immunostained with anti-mouse CD8α-PerCP/Cyanine5.5 (1:200 dilution; BioLegend) or anti-mouse FoxP3-Alexa Fluor 647 antibody (1:250 dilution; BioLegend). For immunofluorescence staining of vasculature, anti-mouse CD31 (1:200 dilution; BD Biosciences) and anti-mouse NG2 (1:100 dilution; Abcam), followed by goat anti-rat Cy3 (1:400 dilution; Jackson ImmunoResearch) and goat anti-rabbit Alexa Fluor 488 (1:100 dilution; Jackson ImmunoResearch). For PD-L1, apoptosis or vasculature staining, anti-mouse PD-L1 antibody (1:2,000 dilution; B7-H1; Bio X Cell), anti-mouse cleaved caspase 3 antibody (1:400 dilution; Cell Signaling Technology) or anti-mouse CD31 antibody (1:200 dilution; BD Biosciences), followed by horseradish peroxidase-conjugated goat anti-rabbit (1:500 dilution; Jackson ImmunoResearch) or goat anti-rat secondary antibody (1:500 dilution; Jackson ImmunoResearch) were applied, respectively. Sections were then developed with 3,3′-diaminobenzidine kits (Vector Laboratories) and counterstained with haematoxylin.
Liu Y., Wang L., Song Q., Ali M., Crowe W.N., Kucera G.L., Hawkins G.A., Soker S., Thomas K.W., Miller L.D., Lu Y., Bellinger C.R., Zhang W., Habib A.A., Petty W.J, & Zhao D. (2021). Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion. Nature nanotechnology, 17(2), 206-216.
+ Open protocol
+ Expand
9

Radioisotope Production and Cellular Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
The radioisotope 211At was produced via 209Bi (α, 2n) 211At reaction through CS-30 cyclotron according to the published protocol [25 (link)]. Bovine serum albumin (BSA), Manganese chloride tetrahydrate (MnCl2·4H2O), and sodium hydroxide (NaOH) were from Sigma-Aldrich. Roswell park memorial institute (RPMI) 1640 medium, penicillin-streptomycin, and fetal bovine serum (FBS) were obtained from Gbico. The cell counting kit-8 (CCK-8) was obtained from Biosharp. The anti-mouse PD-L1 antibody was obtained from BioXcell (clone:10F.9G2). APC anti-mouse CD45(Catalog: 103111), FITC anti-mouse CD3 (Catalog: 100203), BV421™ anti mouse CD4(Catalog: 100437), APC/Cy7 anti-mouse CD8a (Catalog: 100714), PE anti-mouse FOXP3 (Catalog: 126403), FITC anti-mouse CD11c (Catalog: 117305), PE anti-mouse CD86 (Catalog:105007), APC anti-mouse CD80 (Catalog: 104713), PE/Cy7 anti-mouse CD45 (Catalog: 103113), PE anti-mouse CD44(Catalog:103023) and BV421- anti-mouse CD62L (Catalog: 104435) antibodies were obtained from Biolegend, Tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) ELISA kit was purchased from Multisciences Biotech, Co., Ltd.
Zhang J., Li F., Yin Y., Liu N., Zhu M., Zhang H., Liu W., Yang M., Qin S., Fan X., Yang Y., Zhang K, & Yu F. (2022). Alpha radionuclide-chelated radioimmunotherapy promoters enable local radiotherapy/chemodynamic therapy to discourage cancer progression. Biomaterials Research, 26, 44.
+ Open protocol
+ Expand
10

Subcutaneous Bladder Cancer Models

Check if the same lab product or an alternative is used in the 5 most similar protocols
Tumors were established by subcutaneous injection of 3×105 empty vector overexpressed MB49 (MB49-EV) cells or Ifnl3 overexpressed MB49 (MB49-Ifnl3OE) cells into the flank of C57BL/6 and 1×105 MB49-EV or transfected MB49-Ifnl3OE cells into the flank of BALB/c nude mice, respectively. Subcutaneous MB49-EV and MB49-Ifnl3OE bladder cancer models were established in C57BL/6 mice aged 6–8 weeks old to evaluate the effect of anti-PD-L1 treatment. From the seventh day after implantation, the mice were administered intraperitoneally injections, once every 3 days until the end of the experiment, of 100 µg anti-mouse PD-L1 antibody (BioXcell, USA) or Rat isotype IgG (BioXcell, USA) as control. The tumors were measured every 2–3 days, and the volumes were calculated in mm3 using the following formula: volume=[length (mm)×width (mm)2/2. The mice were killed at indicated time or if their tumor volume exceeded 2 cm3 or they exhibited any signs of ulcers.
Wang B., Zhou B., Chen J., Sun X., Yang W., Yang T., Yu H., Chen P., Chen K., Huang X., Fan X., He W., Huang J, & Lin T. (2024). Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses. Journal for Immunotherapy of Cancer, 12(4), e007808.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!